Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Bigfoot Biomedical
Deal Size : $25.0 million
Deal Type : Acquisition
Details : Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks.
Product Name : Omnipod
Product Type : Hormone
Upfront Cash : Undisclosed
February 13, 2023
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Bigfoot Biomedical
Deal Size : $25.0 million
Deal Type : Acquisition
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase III
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 25, 2015
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
